Linking Biochemical and Cellular Efficacy of MERS Coronavirus Main Protease Inhibitors
Van N. T. La, Noa Lahav, Moshe Goldsmith, Mario Rodriguez, Randy Diaz-Tapia, Rebecca Pearl, Briana McGovern, Jared Benjamin, Haim Barr, Kris M. White, Lulu Kang, John D. Chodera, David D. L. Minh · 2026
Read Linking Biochemical and Cellular Efficacy of MERS Coronavirus Main Protease Inhibitors by Van N. T. La, Noa Lahav, Moshe Goldsmith, Mario Rodriguez, Randy Diaz-Tapia, Rebecca Pearl, Briana McGovern, Jared Benjamin, Haim Barr, Kris M. White, Lulu Kang, John D. Chodera, David D. L. Minh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13344468.txt.
Description
Van N. T. La and co-authors compare ways to read drug potency data against the MERS coronavirus main protease in 2026. Candidate blockers oddly switch this enzyme on at low doses and off at high ones, bending the usual dose-response curve and muddying rank order, so the team tested three analysis routes.
Fitting just the inhibition leg of the curve, in two variants, gave potencies that tracked live-virus results in cells. A fuller kinetic model that builds in enzyme pairing and ligand binding, then projects to cell-like enzyme levels, forecast the cellular ranking most accurately. The comparison hands antiviral hunters a surer way to judge compounds against this and similar enzymes.
Catalog record
| CREATOR | Van N. T. La, Noa Lahav, Moshe Goldsmith, Mario Rodriguez, Randy Diaz-Tapia, Rebecca Pearl, Briana McGovern, Jared Benjamin, Haim Barr, Kris M. White, Lulu Kang, John D. Chodera, David D. L. Minh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55673 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |